A

Abbott India Ltd
NSE:ABBOTINDIA

Watchlist Manager
Abbott India Ltd
NSE:ABBOTINDIA
Watchlist
Price: 30 325 INR -0.21% Market Closed
Market Cap: 644.4B INR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one ABBOTINDIA stock under the Base Case scenario is 23 650.81 INR. Compared to the current market price of 30 325 INR, Abbott India Ltd is Overvalued by 22%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ABBOTINDIA Relative Value
Base Case
23 650.81 INR
Overvaluation 22%
Relative Value
Price
A
Worst Case
Base Case
Best Case

Valuation Multiples

10.3
P/S
P/S
Price to Sales
10.3
vs History
17
vs Industry
13
Median 3Y
9.9
Median 5Y
8.7
Industry
2.4
Forward
9.9
More Details
48.3
P/E
P/E
Price to Earnings
48.3
vs History
57
vs Industry
8
Median 3Y
48.4
Median 5Y
48.7
Industry
20.5
Forward
45.3
More Details
63.7
P/OCF
P/OCF
Price to OCF
63.7
vs History
1
vs Industry
6
Median 3Y
50.5
Median 5Y
50.5
Industry
15.6
More Details
70.7
P/FCFE
P/FCFE
Price to FCFE
70.7
vs History
1
vs Industry
7
Median 3Y
56.3
Median 5Y
56.3
Industry
23.1
More Details
18.3
P/B
P/B
Price to Book Value
18.3
vs History
4
vs Industry
2
Median 3Y
15.8
Median 5Y
15.2
Industry
2
More Details
10
EV/S
EV/S
Enterprise Value to Sales
10
vs History
17
vs Industry
13
Median 3Y
9.6
Median 5Y
8.4
Industry
2.5
Forward
9.6
More Details
22.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
22.4
vs History
17
vs Industry
9
Median 3Y
21.1
Median 5Y
18.6
Industry
4.9
More Details
39.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
39.2
vs History
25
vs Industry
9
Median 3Y
38.7
Median 5Y
38.1
Industry
12.3
Forward
36.5
More Details
41.1
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
41.1
vs History
31
vs Industry
10
Median 3Y
40.6
Median 5Y
40.3
Industry
15.5
Forward
35.2
More Details
61.9
EV/OCF
EV/OCF
Enterprise Value to OCF
61.9
vs History
1
vs Industry
7
Median 3Y
48.4
Median 5Y
48.1
Industry
14.1
More Details
64.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
64.8
vs History
1
vs Industry
7
Median 3Y
50.4
Median 5Y
49.5
Industry
17.5
More Details
29
EV/IC
EV/IC
Enterprise Value to IC
29
vs History
61
vs Industry
3
Median 3Y
28.7
Median 5Y
33
Industry
1.8
More Details

Multiples Across Competitors

ABBOTINDIA Competitors Multiples
Abbott India Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Abbott India Ltd
NSE:ABBOTINDIA
644.4B INR 10.3 48.3 39.2 41.1
US
Eli Lilly and Co
NYSE:LLY
707.1B USD 14.4 63.7 34.3 37.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
357.1B USD 4 16.4 12 15.7
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.8 19.5 12.9 14.7
CH
Roche Holding AG
SIX:ROG
205.8B CHF 3.4 24.9 9.3 10.9
CH
Novartis AG
SIX:NOVN
177B CHF 4 16.4 9.7 13
UK
AstraZeneca PLC
LSE:AZN
158.3B GBP 3.8 27.1 130.3 196.5
US
Merck & Co Inc
NYSE:MRK
192.8B USD 3 11.1 8.3 10
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
130B USD 2.1 16.5 7.2 10.1
P/E Multiple
Earnings Growth PEG
IN
A
Abbott India Ltd
NSE:ABBOTINDIA
Average P/E: 27.1
48.3
15%
3.2
US
Eli Lilly and Co
NYSE:LLY
63.7
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
16.4
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.5
18%
1.1
CH
Roche Holding AG
SIX:ROG
24.9
32%
0.8
CH
Novartis AG
SIX:NOVN
16.4
17%
1
UK
AstraZeneca PLC
LSE:AZN
27.1
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.1
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.5
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
A
Abbott India Ltd
NSE:ABBOTINDIA
Average EV/EBITDA: 397.4
39.2
14%
2.8
US
Eli Lilly and Co
NYSE:LLY
34.3
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.3
6%
1.6
CH
Novartis AG
SIX:NOVN
9.7
5%
1.9
UK
AstraZeneca PLC
LSE:AZN
130.3
9%
14.5
US
Merck & Co Inc
NYSE:MRK
8.3
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.2
2%
3.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
A
Abbott India Ltd
NSE:ABBOTINDIA
Average EV/EBIT: 1 700.7
41.1
18%
2.3
US
Eli Lilly and Co
NYSE:LLY
37.4
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
15.7
13%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
14.7
14%
1
CH
Roche Holding AG
SIX:ROG
10.9
6%
1.8
CH
Novartis AG
SIX:NOVN
13
10%
1.3
UK
AstraZeneca PLC
LSE:AZN
196.5
21%
9.4
US
Merck & Co Inc
NYSE:MRK
10
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
10%
1

See Also

Summary
ABBOTINDIA intrinsic value, competitors valuation, and company profile.
DCF Valuation
ABBOTINDIA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ABBOTINDIA stock valuation using valuation multiples.
Wall Street Estimates
ABBOTINDIA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ABBOTINDIA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 254,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.